Your session is about to expire
← Back to Search
Chemotherapy
siG12D-LODER for Pancreatic Cancer (PROTACT Trial)
Phase 2
Waitlist Available
Led By Talia Golan, MD
Research Sponsored by Silenseed Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group
Summary
This trial uses a small device that releases a drug directly into pancreatic tumors, targeting patients who can't have surgery. The device is used with standard treatment to see if it improves the response. Bazedoxifene is being tested to see if it works well with the standard treatment for pancreatic cancer.
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: siG12D-LODER + chemotherapyExperimental Treatment3 Interventions
Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Folfirinox
2018
Completed Phase 3
~760
Find a Location
Who is running the clinical trial?
Silenseed LtdLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
Talia Golan, MDPrincipal InvestigatorSheba Medical Center
1 Previous Clinical Trials
24 Total Patients Enrolled
Eileen M O'Reilly, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
217 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger